Suven Life Sciences Limited is a clinical-stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for neurodegenerative disorders. Established in 1989 and headquartered in Hyderabad, India, the company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and was renamed Suven Life Sciences Limited in 2003.
The company's primary focus is on developing new molecules and compounds within the complex Central Nervous System (CNS) therapeutic area. Most of its lead molecules target niche areas such as cognitive impairments, including amnesia, dementia, narcolepsy, Alzheimer's disease, and delirium. The CNS segment represents the second-largest therapeutic category in the pharmaceutical industry and is experiencing robust growth.
Suven Life Sciences is actively engaged in Drug Discovery and Development of New Chemical Entities (NCEs) for Central Nervous System (CNS) disorders, addressing significant unmet medical needs globally. Its discovery research efforts are concentrated on identifying and developing NCEs that offer best-in-class CNS therapies for conditions like cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, and gastrointestinal motility disorders.
Key research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and serotonergic receptor), and P2X purinoceptor 7 receptor.
The company's product candidates include Masupirdine (SUVN-502) for Alzheimer's disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for depressive disorders.
Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited. The promoter holding in Suven Life Sciences Ltd has been consistent, standing at 70.27% as of March 2025, up from 70.27% as of June 2024. The primary promoter is JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (acting as the sole trustee of Jasti Family Trust), which holds 69.56% of the total equity.
In the financial year 2018-19, a Scheme of Arrangement for Demerger was executed between Suven Life Sciences and Suven Pharmaceuticals Limited. This resulted in a mirror shareholding of Suven Life Sciences in the newly incorporated Suven Pharmaceuticals Limited. Suven Pharmaceuticals Limited, incorporated on November 6, 2018, in Telangana, was carved out as the Resulting Company under this scheme. By an order dated January 6, 2020, of the Hon'ble National Company Law Tribunal (NCLT) Hyderabad Bench, the Contract Research And Manufacturing Services (CRAMS) business undertaking was transferred to Suven Pharma as a going concern from Suven Life Sciences Limited.
Following the demerger, Suven Life Sciences Limited continues to focus on innovative research in Central Nervous System (CNS) disorders, aiming to address significant unmet global medical needs.
The market capitalization of Suven Life Sciences Ltd (SUVEN) was ₹5248.82 Crore as of June 30, 2025. The 52-week high for Suven Life Sciences Ltd (SUVEN) is ₹271.72, and the 52-week low is ₹102.50. Over the last 3 years, Suven Life Sciences Ltd's share price has shown a substantial increase of 235.75% on the BSE.
- Q1 FY25 (Quarter ended March 2025):
- Sales declined by 38.49% to ₹1.47 crore in the quarter ended March 2025, compared to ₹2.39 crore in the previous quarter ended March 2024.
- Net Loss for Suven Life Sciences was reported at ₹43.94 crore in the quarter ended March 2025, an increase from a net loss of ₹26.54 crore in the corresponding quarter of the previous year.
- FY25 Annual Results:
- Sales declined by 43.03% to ₹6.66 crore in the year ended March 2025, compared to ₹11.69 crore in the previous fiscal year ended March 2024.
- For the full fiscal year, the net loss was reported at ₹160.75 crore, an increase from a net loss of ₹105.08 crore in the previous fiscal year ended March 2024.
- Q3 FY25 (Quarter ended December 2024):
- Net Loss for Suven Life Sciences was reported at ₹39.12 crore in the quarter ended December 2024, compared to a net loss of ₹41.76 crore in the previous quarter ended December 2023.
- Sales declined by 34.29% to ₹1.61 crore in the quarter ended December 2024, against ₹2.45 crore in the corresponding quarter of the previous year.
- P/E Ratio: -32.65
- P/B Ratio: 19.44
- Debt: The company is almost debt-free.
The company's operations span across multiple geographies, including India, the USA, Europe, and other regions. The USA is the primary contributor to the company's revenue. Suven Life Sciences generates revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
Suven Life Sciences recently approved a fundraising plan of ₹857 crore, which resulted in a 15% surge in its stock price. The Board of Directors also approved the allotment of 6,40,02,999 Warrants convertible into Equity Shares.
The company remains committed to its core mission of developing innovative treatments for CNS disorders and is strategically positioned as a clinical-stage biopharmaceutical company with significant potential in the expanding neurodegenerative therapeutics market.
